U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689188) titled 'Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa' on July 01.
Brief Summary: This study investigates the efficacy of topical roflumilast foam in patients with HS.
Study Start Date: Aug. 10
Study Type: INTERVENTIONAL
Condition:
Hidradenitis Suppurativa (HS)
Intervention:
DRUG: Roflumilast 0.3% topical foam
Roflumilast 0.3% topical foam applied once daily (QD) to all active hidradenitis suppurativa lesions for 16 weeks.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Harrison Dermatology
Published by HT Digital Content Services with permission from Health Daily Digest...